Paul Hamberg

Paul Hamberg is affiliated with Erasmus MC in the field of Medical Oncology, where he conducts active research in prostate cancer and related urological malignancies. His work is centered on clinical and translational oncology, with a strong focus on biomarker development and treatment response prediction.

• Institution: Erasmus MC
• Division: Medical Oncology

His research interests include prostate cancer, castration-resistant prostate cancer, pharmacokinetics, precision medicine, and immune checkpoint inhibitors. He investigates novel biomarkers such as cell-free DNA aneuploidy scores and T-cell-to-stroma enrichment (TSE) to predict therapeutic outcomes. His work also explores advanced imaging techniques like PSMA PET/CT for cancer management.

The recent articles highlight a strong trend toward personalized oncology, integrating molecular profiling, metabolic insights, and innovative trial designs. His publications span high-impact journals such as Nature Communications and Molecular Oncology, reflecting a multidisciplinary approach that bridges clinical practice and research.

While no specific scientific awards are listed in the provided text, his extensive publication record and collaborative research indicate significant recognition in the oncology community.

Paul Hamberg has contributed to the supervision of at least one research work, as indicated by the 'Supervised Work (1)' mention. His involvement in multiple clinical trials and collaborative studies demonstrates active engagement in research mentoring and team science. There is no mention of specific grants, but his participation in complex trials suggests involvement in funded research initiatives.

He is part of a robust research network at Erasmus MC, collaborating with experts in urology, nuclear medicine, and molecular oncology. His work is embedded in multidisciplinary teams focused on improving outcomes in prostate and renal cancers.